TY - JOUR
T1 - Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort
T2 - The ABIDE project
AU - de Wilde, Arno
AU - Ossenkoppele, Rik
AU - Pelkmans, Wiesje
AU - Bouwman, Femke
AU - Groot, Colin
AU - van Maurik, Ingrid
AU - Zwan, Marissa
AU - Yaqub, Maqsood
AU - Barkhof, Frederik
AU - Lammertsma, Adriaan A.
AU - Biessels, Geert Jan
AU - Scheltens, Philip
AU - van Berckel, Bart N.
AU - van der Flier, Wiesje M.
N1 - Copyright © 2019 The Authors. Published by Elsevier Inc. All rights reserved.
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Introduction: The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. Methods: We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging Taskforce in the AUC, and other clinical utility outcomes. Furthermore, we compared differences in post–positron emission tomography diagnosis and management change between “AUC-consistent” and “AUC-inconsistent” patients. Results: Almost half (250/507) of patients were AUC-consistent. In both AUC-consistent and AUC-inconsistent patients, post–positron emission tomography diagnosis (28%–21%) and management (32%–17%) change was substantial. The Amyloid Imaging Taskforce's definition of appropriate use occurred in 55/507 (13%) patients, detected by the AUC with a sensitivity of 93%, and a specificity of 56%. Diagnostic changes occurred independently of AUC status (sensitivity: 57%, specificity: 53%). Discussion: The current AUC are not sufficiently able to discriminate between patients who will benefit from amyloid positron emission tomography and those who will not.
AB - Introduction: The objective of this study was to assess the usefulness of the appropriate use criteria (AUC) for amyloid imaging in an unselected cohort. Methods: We calculated sensitivity and specificity of appropriate use (increased confidence and management change), as defined by Amyloid Imaging Taskforce in the AUC, and other clinical utility outcomes. Furthermore, we compared differences in post–positron emission tomography diagnosis and management change between “AUC-consistent” and “AUC-inconsistent” patients. Results: Almost half (250/507) of patients were AUC-consistent. In both AUC-consistent and AUC-inconsistent patients, post–positron emission tomography diagnosis (28%–21%) and management (32%–17%) change was substantial. The Amyloid Imaging Taskforce's definition of appropriate use occurred in 55/507 (13%) patients, detected by the AUC with a sensitivity of 93%, and a specificity of 56%. Diagnostic changes occurred independently of AUC status (sensitivity: 57%, specificity: 53%). Discussion: The current AUC are not sufficiently able to discriminate between patients who will benefit from amyloid positron emission tomography and those who will not.
KW - Alzheimer's disease
KW - Amyloid
KW - Appropriate use criteria
KW - Clinical practice
KW - Dementia
KW - Positron emission tomography
UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85072845987&origin=inward
UR - https://www.ncbi.nlm.nih.gov/pubmed/31594684
U2 - 10.1016/j.jalz.2019.07.003
DO - 10.1016/j.jalz.2019.07.003
M3 - Article
C2 - 31594684
SN - 1552-5260
VL - 15
SP - 1458
EP - 1467
JO - Alzheimers & Dementia
JF - Alzheimers & Dementia
IS - 11
ER -